摘要
miRNAs是非编码RNA分子,它们的反常调节可能导致癌症的发生。但是,miRNA功能紊乱是怎样导致弥漫性大B细胞淋巴瘤(DLBCL)的机制还没有很好的确认。在这项研究中,我们分析了在4个DLBCL细胞株和168个病人样本中miR-224的表达,我们发现miR-224的表达在DLBCL细胞株中与正常B细胞比较是下调的,但是在生发中心B细胞样和活化B细胞样之间在统计学上没有差异。利用生物信息学预测与荧光素酶报告化验分析,我们揭示了miR-224通过结合到CD59的3’端非翻译区的方式直接下调CD59表达。我们也使用免疫组化染色方式染色人DLBCL样本细胞的CD59,并分析miR-224,CD59的表达和分别使用利妥昔单抗,环磷酰胺,阿霉素,长春新碱和泼尼松(R-CHOP)治疗的DLBCL病人的总的/复发生存率的相关性。我们发现miR-224可能导致DLBCL的发生,更重要的是miR-224和CD59的表达能够预测R-CHOP治疗DLBCL病人后的反应和效果。
关键词: CD59,致弥漫性大B细胞淋巴瘤 (DLBCL),小分子RNA,miR-224, R-CHOP.
图形摘要
Current Cancer Drug Targets
Title:Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP
Volume: 14 Issue: 7
Author(s): Guoqi Song, Guorong Song, Huiyun Ni, Ling Gu, Hong Liu, Baoan Chen, Bangshun He, Yuqin Pan, Shukui Wang and William C. Cho
Affiliation:
关键词: CD59,致弥漫性大B细胞淋巴瘤 (DLBCL),小分子RNA,miR-224, R-CHOP.
摘要: miRNAs are non-coding RNA molecules; their deregulations may contribute to cancer pathogenesis. However, the mechanisms of how miRNA dysfunction contributes to the lymphomagenesis of diffuse large B-cell lymphoma (DLBCL) are not well established. In this study, we analyzed the expression of miR-224 in four DLBCL cell lines and 168 patients’ specimens. We found that the expression of miR-224 in DLBCL was down-regulated compared with normal B-cell but was not statistically different between the germinal center B-cell-like-type and the activated B-cell-like-type. Using bioinformatics prediction and luciferase report assays, we demonstrated that miR-224 directly down-regulated CD59 expression by binding to its 3’-untranslated region. We also used immunohistochemical staining of CD59 in human DLBCL specimens and analyzed the relationship between the expression of miR-224, CD59 and the overall/progress-free survival of DLBCL patients who were uniformly treated with rituximab,cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP). We found that miR-224 may contribute to DLBCL pathogenesis. Most importantly, the expression of miR-224 and CD59 can predict the response and outcome of DLBCL patients treated with R-CHOP.
Export Options
About this article
Cite this article as:
Song Guoqi, Song Guorong, Ni Huiyun, Gu Ling, Liu Hong, Chen Baoan, He Bangshun, Pan Yuqin, Wang Shukui and Cho C. William, Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP, Current Cancer Drug Targets 2014; 14 (7) . https://dx.doi.org/10.2174/1568009614666140818211103
DOI https://dx.doi.org/10.2174/1568009614666140818211103 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy Diet and Heart Health: Moderate Wine Drinking Strengthens the Cardioprotective Effects of Fish Consumption
Current Pharmaceutical Biotechnology Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging NAD(P) Biosynthesis Enzymes as Potential Targets for Selective Drug Design
Current Medicinal Chemistry Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma
Current Cancer Drug Targets Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Ovarian Toxicity: From Environmental Exposure to Chemotherapy
Current Pharmaceutical Design Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors
Current Molecular Medicine